Pneumococcal 13-Valent Conjugate Vaccine (Yuxi Walvax Biotechnology)

13价肺炎球菌多糖结合疫苗（玉溪沃森生物技术）

Report date: 2026/03/13 20:02:36

Base Information

Drug NamePneumococcal 13-Valent Conjugate Vaccine (Yuxi Walvax Biotechnology)
Drug Alias Name13价肺炎结合疫苗（玉溪沃森生物技术）Walvax PCV13-TT十三价肺炎球菌多糖结合疫苗（玉溪沃森生物技术）沃安欣
ClassificationVaccines > Vaccine type > Multivalent vaccineVaccines > Development/production technology > Conjugated vaccineVaccines > Biological material > Bacterial vaccine +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsPneumoniaPneumococcal Infections
Global Approved IndicationsPneumococcal Infections
Approved Indications in ChinaPneumococcal Infections
Original Approved Country/TerritoryMainland China
Original Approved Date2019/12/30
Country/TerritoryIndonesiaMoroccoMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesWalvax Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMarocVax SARLPT Etana Biotechnologies IndonesiaYuxi Walvax Biotechnology Co Ltd
Inactive CompaniesWalvax Biotechnology Co Ltd
Active IndicationsPneumococcal Infections
Inactive IndicationsPneumonia

Other Information

ATC CodeJ07AL02
Related LinksN/A